Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,597 across all filing types
Latest filing 2014-10-08 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
投资者关系管理制度（2014年10月）
Governance Information Classification · 95% confidence The document is titled '投资者关系管理制度' which translates to 'Investor Relations Management System'. It outlines the principles, objectives, responsibilities, and procedures for managing investor relations within the company. The content focuses on governance, communication policies, and compliance with laws and stock exchange regulations. It does not contain financial statements, earnings data, or audit information. It is a governance-related document detailing internal rules and practices for investor relations management rather than a report or announcement of financial results or corporate actions. Therefore, it fits best under Governance Information (CGR). The document length (5132 characters) and detailed procedural content support this classification rather than a brief announcement or regulatory filing.
2014-10-08 Chinese
独立董事提名人声明
Board/Management Information Classification · 95% confidence The document is a public statement from the board nominating an independent director candidate for the company's board. It details the qualifications, compliance with regulatory requirements, and declarations related to the nominee's independence and eligibility. There are no financial statements, earnings data, or report attachments. The content is focused on board/management information, specifically about a director nomination. The document length is short (3117 characters) and it is not an announcement of a report publication but a formal nomination statement. Therefore, the appropriate classification is Board/Management Information (MANG).
2014-10-08 Chinese
信息披露事务管理制度（2014年10月）
Governance Information Classification · 100% confidence The document is titled '信息披露事务管理制度' which translates to 'Information Disclosure Management System' and is issued by Guangdong Taicheng Pharmaceutical Co., Ltd. It details the company's internal policies and procedures for information disclosure, including legal references, responsibilities of the board and secretary, principles of disclosure, approval procedures, types of reports (annual, interim, quarterly, and temporary reports), confidentiality, penalties for violations, and other governance-related rules. It does not contain actual financial data, financial statements, or results but rather outlines the governance and procedural framework for disclosure compliance. This aligns with a Governance Information report, which details the company's internal rules, board structure, and governance practices. The document is lengthy (over 10,000 characters) and is not a mere announcement or certification. Therefore, the appropriate classification is Governance Information (CGR).
2014-10-08 Chinese
内幕信息知情人登记管理制度（2014年10月）
Governance Information Classification · 95% confidence The document is titled '内幕信息知情人登记管理制度' which translates to 'Insider Information Insider Registration Management System' and is issued by Guangdong Taicheng Pharmaceutical Co., Ltd. It details the company's internal policies and procedures for managing insider information, including definitions, scope, responsibilities, confidentiality, and record-keeping requirements. It references relevant Chinese laws and regulatory bodies such as the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document includes internal control policies, confidentiality agreements, and procedures for insider information registration and management. It does not contain financial statements, earnings data, or any form of financial results. It is a governance-related document outlining internal rules and compliance practices related to insider information management. Therefore, it fits best under Governance Information (CGR). The document length (9,324 characters) and content confirm it is a full policy document, not a brief announcement or certification, so it is not RNS or RPA. Hence, the classification is CGR with high confidence.
2014-10-08 Chinese
独立董事关于更换独立董事的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding the replacement of an independent director, referencing compliance with relevant laws, company articles, and regulatory guidance from the China Securities Regulatory Commission. It discusses nomination and voting procedures and confirms the qualifications of the proposed independent director candidate. There is no financial data, no report publication, no voting results announcement, and no mention of a general meeting or shareholder vote results. The document is a management/board-related announcement about changes in the board composition, specifically about independent directors. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board changes, not a full report or announcement of voting results.
2014-10-08 Chinese
关于召开2014年第三次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening a 2014 third extraordinary general meeting of shareholders for Guangdong Taicheng Pharmaceutical Co., Ltd. It includes information about the meeting time, location, agenda items, voting procedures (both onsite and online), registration methods, and proxy forms. The content focuses on informing shareholders about the meeting logistics and the proposals to be voted on, such as nomination of independent directors, changes to business scope, and amendments to fundraising management systems. There are no financial statements, audit opinions, or earnings data presented. The document is not a report itself but a formal announcement and invitation to a shareholders meeting with voting instructions. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2014-10-08 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.